Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CyclASol Safety and Tolerability in Healthy Volunteers
NCT02113293Phase 1Completed
- Sponsor
- Novaliq GmbH
- Start
- Mar 2014
- Primary completion
- May 2014
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in dry eye disease (DED) comparing CyclASol with Placebo (2 arms). Primary endpoint: Local tolerability measured by the rate and severity of drug-related adverse events of the eyes at 45 days. Started Mar 2014; status: completed.
02
Drugs
vevye
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT02113293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02113293.